1
|
Mallet A, Lusque A, Levy C, Pistilli B, Brain E, Pasquier D, Debled M, Thery JC, Gonçalves A, Desmoulins I, De La Motte Rouge T, Faure C, Ferrero JM, Eymard JC, Mouret-Reynier MA, Patsouris A, Cottu P, Dalenc F, Petit T, Payen O, Uwer L, Guiu S, Sébastien Frenel J. Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer. Ther Adv Med Oncol 2022; 14:17588359211070362. [PMID: 35082924 PMCID: PMC8785354 DOI: 10.1177/17588359211070362] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Accepted: 12/13/2021] [Indexed: 01/09/2023] Open
Abstract
Background: Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues. De novo metastatic breast cancer (MBC) in young women is an even more serious condition, with limited data available. Methods: We evaluated management of women aged ⩽40 years with de novo MBC in a real-life national multicentre cohort of 22,463 patients treated between 2008 and 2016 (NCT0327531). Our primary objective was to compare overall survival (OS) in young women versus women aged 41–69 years. The secondary objectives were to compare first-line progression-free survival (PFS1) and to describe treatment patterns. Results: Of the 4524 women included, 598 (13%) were ⩽40 years. Median age at MBC diagnosis was 36 years (range = 20–40). Compared with women aged 41–69 years, young women had more grade III tumours (49% versus 35.7%, p < 0.0001), human epidermal growth factor receptor 2 amplified (HER2+) disease (34.6% versus 26.4%, p < 0.0001) and HR–/HER2– disease known as “triple negative breast cancer” (TNBC) (17.1% versus 12.7%, p < 0.0001). BRCA testing was performed for 260 young women, with a BRCA1/2 mutation in 44 (17% of those tested) In young HR+/HER2– patients, chemotherapy (CT) was given as the frontline treatment more frequently compared with older ones (89.6% versus 68.8%, respectively, p < 0.0001). After median follow-up of 49.7 months (95% confidence interval, CI = 48.0–51.7), the median OS of young women was 58.5 months, 20.7 months and not attained in HR+/HER2–, TNBC and HER2+ subgroups, respectively. After adjustment for histological subtype, tumour grade, and number and type of metastasis, young women had significantly better OS compared with older ones, except for the TNBC subgroup, for which the outcome was similar. PFS1 was statistically different only in the TNBC subgroup, with 7.8 months for young women and 6.3 months for older women ( p = 0.0015). Conclusion: De novo MBC affects a significant proportion of young women. A subgroup of these patients achieves long OS and merits multidisciplinary care.
Collapse
Affiliation(s)
- Amélie Mallet
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest – René Gauducheau, Saint-Herblain, France
| | - Amélie Lusque
- Department of Biostatistics, Institut Claudius Regaud – IUCT Oncopole, Toulouse, France
| | - Christelle Levy
- Department of Medical Oncology, Centre François Baclesse, Caen, France
| | - Barbara Pistilli
- Department of Cancer Medicine, Gustave Roussy, Villejuif, France
| | - Etienne Brain
- Department of Medical Oncology, Institut Curie, Paris, France
| | - David Pasquier
- Department of Radiation Oncology, Centre Oscar Lambret, Lille, France
| | - Marc Debled
- Department of Medical Oncology, Institut Bergonie, Bordeaux, France
| | | | - Anthony Gonçalves
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France
| | - Isabelle Desmoulins
- Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France
| | | | - Christelle Faure
- Department of Surgery Oncology, Centre Léon Bérard, Lyon, France
| | - Jean Marc Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France
| | | | | | - Anne Patsouris
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest – Paul Papin, Angers, France
| | - Paul Cottu
- Department of Medical Oncology, Etablissement Hospitalier Institut Curie, Paris, France
| | - Florence Dalenc
- Department of Medical Oncology, Institut Claudius Regaud – IUCT Oncopole, Toulouse, France
| | - Thierry Petit
- Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France
| | - Olivier Payen
- Department of Real World Data, Data Unit, Unicancer, Paris, France
| | - Lionel Uwer
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
| | - Séverine Guiu
- Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France
| | - Jean Sébastien Frenel
- Department of Medical Oncology, Institut de Cancérologie de l’Ouest – René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France
| |
Collapse
|
2
|
Clatot F, Lebret L, Rigal O, Lefebvre L, Dandoy S, Cabourg M, Moldovan C, Veresezan O, Thery JC, Petrau C, Lebreton M, Guérault F, Ebran M, Gouley-Toutain C, Bon-Mardion N, Bastit V, Di Fiore F, Dubray BM, Lequesne J, Thureau S. Factors associated with non-completion of radiation therapy (RT) or radiochemotherapy (RTCT) in head and neck squamous cell carcinoma (HNSCC): A prospective study. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e17568] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17568 Background: Although numerous factors have been reported to increase RT/RTCT toxicity, identification of patients with high risk of toxicities is lacking. Methods: The monocentric NutriNeck study (NCT02900963) recruited all HNSCC patients between 2014 and 2018 treated by RT or RTCT. Patients fed by enteral nutrition before RT initiation were excluded. All clinical and biological, planned RT or RTCT parameters were collected at baseline. A daily monitoring of the weight and a weekly evaluation of clinical, biological and food intake during RT/RTCT were performed. A nutritional intervention by enteral feeding was systematically proposed in case of 2 kg weight loss under treatment. Complete treatment was defined as full planned RT doses without more than 3 days interruption, and full planned doses of cisplatin and cetuximab if indicated. Primary endpoint assessed factors associated with non-completion of the planned treatment. Secondary endpoint assessed factors associated with use of enteral nutrition during treatment. A p value < 0.01 was considered significant. Results: Among the 249 HNSCC patients included, 118 (47%) were treated by RT and 131 (53%) by RTCT. 63 patients (25%) did not complete treatment: 3/118 (2.5%) in the RT group compared to 60/131 (45.8%) the RTCT group, p < 0.0001. Median weight lost during treatment (7 vs 3.8 kg, p < 0.0001) and grade 3 toxicities (53 vs 33%, p = 0.006) were more frequent in patients with incomplete RT/RTCT. Nutritional intervention was performed in 111 patients: 28 (23.7%) with RT and 83 (62.6%) with RTCT (p < 0.0001). Week 4 was associated with the higher rate of enteral nutrition initiation in both RT and RTCT groups. Among RTCT group, weight loss during treatment (OR 1.2 for each kg, p < 0.0001) and use of enteral feeding (OR 2.7, p = 0.005) were associated with incomplete treatment in multivariate analysis. Of note, 48 patients refused enteral nutrition while indicated, they had comparable grade 3 toxicities and weight loss during treatment compared to the 111 patients who accepted enteral nutrition. Conclusions: Incomplete treatment is overwhelmingly associated with RTCT rather than RT. Baseline clinical, biological features or treatment volume/dose are not associated with incomplete treatment. Enteral nutrition initiated during treatment is poorly efficient.
Collapse
Affiliation(s)
- Florian Clatot
- INSERM U1245, IRON Group, Centre Henri Becquerel, University Hospital, University of Normandy, Rouen, France
| | | | - Olivier Rigal
- Centre Henri-Becquerel, Department of Medical Oncology, Rouen, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Frédéric Di Fiore
- Digestive Oncology Unit, IRON group, Rouen Hospital, University of Normandy, Rouen, France
| | | | | | | |
Collapse
|
3
|
Hollebecque A, Bahleda R, Thery JC, Faivre L, Le Deley MC, Paci A, Varga A, Gazzah A, Massard C, Poinsignon V, Malekzadeh K, Ribrag V, ANGEVIN ERIC, Postel-Vinay S, Gomez-Roca CA, Gharib M, Dufour F, Soria JC, Spano JP. Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.2599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Antoine Hollebecque
- Drug Development Department, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France
| | - Rastislav Bahleda
- Drug Development Department, Gustave Roussy Institute, Villejuif, France
| | | | | | | | - Angelo Paci
- Gustave Roussy Cancer Campus, Villejuif, France
| | | | - Anas Gazzah
- Drug Development Department (DITEP), Gustave Roussy Institute, Villejuif, France
| | | | | | | | | | | | - Sophie Postel-Vinay
- Gustave-Roussy Cancer Campus, Drug Development Department, Villejuif, France
| | | | | | | | | | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital - INSERM UMR_S 1136, Paris, France
| |
Collapse
|
4
|
Launay-Vacher V, Janus N, Scotte F, Ray-Coquard IL, Beuzeboc P, Daniel C, Gligorov J, Selle F, Goldwasser F, Mir O, Spano JP, Thery JC, Rey JB, Jouannaud C, Morere JF, Elaidi RT, Dorent R, Deray G, Oudard S. Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e16056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | | | | | | | | | | | - Frédéric Selle
- Universite Pierre et Marie Curie, Oncology, GHU-Est Tenon, Paris, France
| | - Francois Goldwasser
- Medical Oncology, Paris Descartes University, Cochin - Port Royal Hospital, AP-HP, Paris, France
| | | | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital - INSERM UMR_S 1136, Paris, France
| | - Jean Christophe Thery
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | | | | | | | - Reza-Thierry Elaidi
- Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | | |
Collapse
|
5
|
Launay-Vacher V, Janus N, Ray-Coquard IL, Gligorov J, Selle F, Beuzeboc P, Daniel C, Spano JP, Thery JC, Goldwasser F, Mir O, Rey JB, Jouannaud C, Morere JF, Oudard S, Deray G, Scotte F. Hypertension, proteinuria, and overall survival in elderly cancer patients treated with bevacizumab. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.31_suppl.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
186 Background: MARS is a multicentric, non-interventional, prospective study which first reported the high prevalence of both baseline and de novo hypertension (HTN) and proteinuria (Pu) in several sub group of cancer patients [Gligorov J et al. SABCS 2013; Ray-Coquard I et al. ASCO GI 2014; Ray-Coquard I et al. ASCO GU 2014; Goldwasser F et al. ECC 2013; Launay-Vacher V et al. ASCO 2013]. In this sub-group analysis, we focused on elderly cancer (EC) patients treated by bevacizumab. Methods: MARS included 1,124 patients, all naïve of any previous anti-VEGF treatment. A First Renal Assessment was performed at baseline before the anti-VEGF was started with periodic follow-up for 1 year. Elderly was defined as age ≥65 years at inclusion. Univariate (UA) and multivariate analyses (MA) tested the associations of HTN and Pu, at baseline or de novo, with overall survival (OS) (pre-planned) in EC patients. Results: 845 patients treated with bevacizumab were included. Among them 226 were EC patients (colorectal 81, breast 78, ovarian 26, lung 22). At inclusion, HTA was statistically higher in EC patients (table), mean aMDRD was 79.6 ml/min/1.73m2 and 15.1% had aMDRD<60. De novo HTA; de novo Pu and Scr increase were not statistically more frequent in EC patients than in non-EC patients. In addition, renal function decreased by -4.1 ml/min/1.73m²/year and 16.2% had aMDRD<60 at the end of follow-up. Baseline and de novoHTN and Pu were not associated with reduced OS in EC patients in both UA and MA analyses. Conclusions: There were no differences in term of renovascular safety in EC patients treated by bevacizumab. Furthermore, HTN and Pu were not associated with OS in EC patients treated by bevacizumab. Therefore, renovascular events should not be contraindicated at the initiation of the treatment or when the patient is already on treatment. [Table: see text]
Collapse
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | | | - Joseph Gligorov
- Assistance Publique–Hôpitaux de Paris, Tenon APREC, CancerEst, University Paris VI, Paris, France
| | - Frédéric Selle
- Universite Pierre et Marie Curie, Oncology, GHU-Est Tenon, Paris, France
| | | | | | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital, Paris, France
| | - Jean Christophe Thery
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | | | | | | | | | - Stephane Oudard
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France
| | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | - Florian Scotte
- Supportive Care Unit, Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
| |
Collapse
|
6
|
Launay-Vacher V, Janus N, Ray-Coquard IL, Beuzeboc P, Daniel C, Gligorov J, Selle F, Goldwasser F, Mir O, Spano JP, Thery JC, Rey JB, Jouannaud C, Morere JF, Oudard S, Scotte F, Azizi M, Dorent R, Deray G. Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.2548] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | | | | | | | - Joseph Gligorov
- Assistance Publique–Hôpitaux de Paris, Tenon APREC, CancerEst, University Paris VI, Paris, France
| | - Frédéric Selle
- Universite Pierre et Marie Curie, Oncology, GHU-Est Tenon, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | | | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital, Paris, France
| | - Jean Christophe Thery
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | | | | | | | - Stephane Oudard
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, René Descartes University, Paris, France
| | - Florian Scotte
- Supportive Care Functionnal Unit, Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
| | - Michel Azizi
- Arterial Hypertensive Department, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| |
Collapse
|
7
|
Ray-Coquard IL, Janus N, Goldwasser F, Mir O, Oudard S, Scotte F, Spano JP, Thery JC, Beuzeboc P, Daniel C, Rey JB, Jouannaud C, Gligorov J, Morere JF, Azizi M, Dorent R, Deray G, Launay-Vacher V. Results of the MARS study on the management of antiangiogenics’ renovascular safety in renal cell carcinoma. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.4_suppl.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
394 Background: MARS is a prospective multicentric study conducted to assess the renovascular tolerance of anti-VEGF drugs (AVD) in the clinical setting in France, in a number of different tumor types. Methods: Patients (pts) from 8 centres were included when they were 1) naïve of any AVD and 2) about to start treatment with an AVD, from 2009 to 2012, with a follow-up (f/u) of 1 year. Data collected included: gender, age, serum creatinine (SCr), HTN, hematuria (Hu) and dipstick Pu, at baseline and at each visit during f/u. This sub-group analysis presents the results for renal cell carcinoma (RCC) pts receiving sunitinib. Results: 1,124 pts were included. 137 had RCC and 112 received sunitinib. Median age: 61.0 years. Visceral, bone and cerebral metastasis frequencies were 71.4, 42.0 and 12.5%, respectively. All except 3 pts, had at least one kind of metastasis. At inclusion, HTN prevalence was 43.8%. Baseline renal assessment retrieved: Pu 15.6%, Hu 8.1%, mean aMDRD 69.4 ml/min/1.73m2. The incidence of de novo Pu and HTN during f/u was 75.0 and 21.4% (Table). All pts with Pu at inclusion improved or remained stable. Among pts with de novo Pu, 75.8% afterwards improved/normalized. Mean aMDRD was 72.2 at the end of f/u. 0.7% had grade 3 SCr increase (no grade 4). No thrombotic micro-angiopathy (TMA) was reported. Conclusions: These results on the renovascular safety of AVD in RCC patients showed that 1) TMA is rare, 2) Pu develops in 75.0% of the pts, 3) 21.4% developed HTN, Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Collapse
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Olivier Mir
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Stephane Oudard
- Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | - Florian Scotte
- Supportive Care Functionnal Unit, Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
| | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital, Paris, France
| | - Jean Christophe Thery
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | | | | | | | | | - Joseph Gligorov
- Assistance Publique–Hôpitaux de Paris, Tenon APREC, CancerEst, University Paris VI, Paris, France
| | | | - Michel Azizi
- Arterial Hypertensive Department, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | | |
Collapse
|
8
|
Ray-Coquard I, Janus N, Spano JP, Thery JC, Goldwasser F, Mir O, Beuzeboc P, Daniel C, Morere JF, Rey JB, Jouannaud C, Oudard S, Scotte F, Azizi M, Dorent R, Deray G, Launay-Vacher V. Results of the MARS study on the management of antiangiogenics’ renovascular safety in colorectal cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.3_suppl.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
466 Background: MARS is a prospective multicentric study conducted to assess the renovascular tolerance of anti-VEGF drugs (AVD) in the clinical setting in France, in a number of different tumor types. Methods: Patients (pts) from 8 centers were included when they were 1) naive of any AVD and 2) about to start treatment with an AVD, from 2009 to 2012, with a follow-up (f/u) of 1 year. Data collected included: gender, age, serum creatinine (SCr), HTN, hematuria (Hu) and dipstick Pu, at baseline and at each visit during f/u. This subgroup analysis presents the results for colorectal cancer (CRC) pts receiving bevacizumab (BVZ). Results: 1,124 pts were included. 200 had CRC and all but 5 received BVZ. Median age: 63.2 years. Visceral, bone, and cerebral metastasis frequencies were 91.3, 10.8, and 0.5%, respectively. All pts presented metastasis. At inclusion, HTN prevalence was 26.2%. Baseline renal assessment retrieved: Pu 30.6%, Hu 10.1%, mean aMDRD 91.1 ml/min/1.73m2. The incidence of de novo Pu and HTN during f/u was 78.2 and 16.1% (Table). 75.6% of pts with Pu at inclusion improved or remained stable. Among pts with de novo Pu, 60.8% afterward improved/normalized. No grade 4 Pu has been reported (at inclusion or during f/u). Renal function decreased with a mean aMDRD of 90.3 at the end of f/u. 5.9% had grade 2 SCr increase (no grade 3-4). No thrombotic micro-angiopathy (TMA) was reported. Conclusions: These results on the renovascular safety of BVZ in CC patients showed that 1) TMA is rare, 2) Pu develops in 78.2% of the pts (no grade 4), 3) 16.1% developed HTN. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Collapse
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital, Paris, France
| | - Jean Christophe Thery
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Olivier Mir
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Paris, France
| | | | | | | | | | | | - Stephane Oudard
- Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | - Florian Scotte
- Supportive Care Functionnal Unit, Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
| | - Michel Azizi
- Arterial Hypertensive Department, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | | |
Collapse
|
9
|
Launay-Vacher V, Janus N, Selle F, Goldwasser F, Mir O, Spano JP, Thery JC, Beuzeboc P, Rey JB, Jouannaud C, Morere JF, Oudard S, Gligorov J, Azizi M, Dorent R, Deray G, Ray-Coquard IL, Scotte F. Results of the MARS study on the management of antiangiogenics’ renovascular safety in ovarian cancer. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.5567] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5567 Background: Anti-VEGF drugs (AVD) are widely used in cancer patients (pts). Hypertension (HTN) and proteinuria (Pu) are class-side-effects of AVD, related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of these drugs in the clinical setting. Methods: This multicentric, prospective, observational study evaluated the renovascular safety of AVD in pts naive from any AVD, conducted in 7 centres in France, from 2009 to 2012, with a follow-up (f/u) of 1 year. Data collected included: gender, age, serum creatinine (SCr), HTN, hematuria (Hu) and dipstick Pu, at baseline and at each visit. Results: 1,124 pts were included. 79 pts had ovarian cancer (OC) and all received bevacizumab. Median age at inclusion was 61 years. Visceral, bone and cerebral metastasis frequencies were 74.1, 52.7 and 6.0%, respectively. HTN prevalence was 16.5%. Baseline renal assessment retrieved: Pu 36.0%, Hu 21.3%, mean aMDRD 83.0 ml/min/1.73m2 and 5 pts with aMDRD<60. The incidence of de novo Pu and HTA during f/u was 56.8 and 21.2% (Table). 88.9 % of pts with Pu at inclusion improved or remained stable. Among pts with de novo Pu, 64.0% afterwards improved/normalized. No Grade 4 Pu has been reported (at inclusion or during f/u). Renal function remained stable with a mean aMDRD of 83.2 at the end of f/u. 6.0% had grade 2 SCr increase (no grade 3-4). No thrombotic micro-angiopathy (TMA) was reported. Conclusions: These results on the renovascular safety of bevacizumab in OC patients showed that 1) TMA is rare, 2) Pu develops in 56.8% of the pts, however with only 1 Grade 3/4, 3) 21.2% developed HTN, and 4) aMDRD was stable. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Collapse
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | - Frédéric Selle
- Universite Pierre et Marie Curie, Oncology, GHU-Est Tenon, Paris, France
| | - Francois Goldwasser
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Olivier Mir
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital, Paris, France
| | | | | | | | | | | | - Stephane Oudard
- Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | - Joseph Gligorov
- Assistance Publique–Hôpitaux de Paris, Tenon APREC, CancerEst, University Paris VI, Paris, France
| | - Michel Azizi
- Arterial Hypertensive Department, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | | | - Florian Scotte
- Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
| |
Collapse
|
10
|
Gligorov J, Janus N, Daniel C, Beuzeboc P, Ray-Coquard I, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Scotte F, Oudard S, Azizi M, Dorent R, Deray G, Launay-Vacher V. Results of the MARS study on the management of antiangiogenics’ renovascular safety in breast cancer. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e12504] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12504 Background: Anti-VEGF drugs (AVD) are widely used in cancer patients (pts). Hypertension (HTN) and proteinuria (Pu) are class-side-effects of AVD, related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of these drugs in the clinical setting. Methods: This multicentric, prospective, observational study evaluated the renovascular safety of AVD in pts naive from any AVD, conducted in 7 centres in France, from 2009 to 2012, with a follow-up (f/u) of 1 year. Data collected included: gender, age, serum creatinine (SCr), diabetes, HTN, hematuria (Hu) and dipstick Pu, at baseline and at each visit. Results: 1,124 pts were included; 402 breast cancer (BC) pts received bevacizumab. Median age at inclusion was 55 years. Visceral, bone and cerebral metastasis frequencies were 74.7, 5.1 and 2.5%, respectively. HTN prevalences: 12.4%. Baseline renal assessment retrieved: Pu 23.9%, Hu 16.2%, mean aMDRD 96.4 ml/min/1.73m2 and 14 pts with aMDRD<60. The incidence of de novo Pu and HTN during f/u was 61.7 and 16.8% (Table). 69.7 % of pts with Pu at inclusion improved or remained stable. Among pts with de novo Pu, 75.7% afterwards improved/normalized. No grade 4 Pu has been reported. Renal function remained stable with a mean aMDRD of 96.2 at the end of f/u. 7.4% had grade 2-3 SCr increase (no grade 3-4). No thrombotic micro-angiopathy (TMA) was reported. Conclusions: These results on the renovascular safety of bevacizumab in BC patients showed that 1) TMA is rare, 2) Grade 3 Pu developed in 4.6% of pts, with no grade 4, 3) less than 17% developed HTN, and 4) aMDRD was stable. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Collapse
Affiliation(s)
- Joseph Gligorov
- Assistance Publique–Hôpitaux de Paris, Tenon APREC, CancerEst, University Paris VI, Paris, France
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | | | | | | | | | | | - Jean-Philippe Spano
- Department of Medical Oncology, Pitié-Salpêtrière University Hospital, Paris, France
| | | | | | - Francois Goldwasser
- Cochin Hospital, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Olivier Mir
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Paris, France
| | - Florian Scotte
- Medical Oncology Department, Georges Pompidou European Hospital, Paris, France
| | - Stephane Oudard
- Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | - Michel Azizi
- Arterial Hypertensive Department, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | | |
Collapse
|
11
|
Launay-Vacher V, Janus N, Gligorov J, Selle F, Goldwasser F, Mir O, Spano JP, Thery JC, Beuzeboc P, Daniel C, Rey JB, Jouannaud C, Morere JF, Oudard S, Azizi M, Dorent R, Deray G, Ray-Coquard I. Management of antiangiogenics’ renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.5067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5067 Background: Anti-VEGF drugs (AVD) are widely used in cancer patients (pts). Hypertension (HTN) and proteinuria (Pu) are class-side-effects of AVD, related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of these drugs in the clinical setting. Methods: Hypertension (HTN) and proteinuria (Pu) are class-side-effects of anti-VEGF drugs (AVD), related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of these drugs in the clinical setting. Results: Among 77 OC pts been included, 38 completed the study to date (1-year follow-up (f/u)). Median age at inclusion (introduction of the AVD) was 62 years. Diabetes and HTN prevalences were 5.2% and 7.9%, respectively. Baseline renal assessment retrieved: Pu 13.2%, Hu 7.9%, mean aMDRD 80.9 ml/min/1.73m2 and 3 pts with aMDRD<60. The incidence of de novo Pu during f/u was 36.4% (Table). All pts with Pu at inclusion improved, except one. Among pts with de novo Pu, 58.3% afterwards improved/normalized. No Grade 3/4 Pu has been reported (at inclusion or during f/u) and no Hu. 17.1% developed HTN. In addition, a mean renal function decrease of -2.7 ml/min/1.73m2/year was observed and 4 pts had aMDRD<60 at the end of f/u. 36.4% had grade 1 SCr increase (median increase of 15.9%) No thrombotic micro-angiopathy (TMA) has been reported. Conclusions: The results of the MARS subgroup of OC pts shows that 1) TMA remains rare, 2) Pu develops in 36.4% of the pts, however with no Grade 3/4, 3) less than 20% developed HTN, and 4) renal function was not especially impaired. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM et Al. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Collapse
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | - Joseph Gligorov
- Hopital Tenon, AP-HP, Université Pierre et Marie Curie, Paris, France
| | | | - Francois Goldwasser
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Olivier Mir
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Jean-Philippe Spano
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | - Jean Christophe Thery
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | | | | | | | | | | | - Stephane Oudard
- Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | - Michel Azizi
- Arterial Hypertensive Department, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | | |
Collapse
|
12
|
Daniel C, Janus N, Rey JB, Beuzeboc P, Ray-Coquard I, Gligorov J, Spano JP, Thery JC, Jouannaud C, Goldwasser F, Mir O, Morere JF, Oudard S, Azizi M, Dorent R, Deray G, Launay-Vacher V. Management of antiangiogenics’ renovascular safety in breast cancer subgroup and intermediate results of the MARS study. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1095 Background: Hypertension (HTN) and proteinuria (Pu) are class-side-effects of anti-VEGF drugs (AVD), related to the inhibition of the VEGF pathway. The MARS study has been conducted to assess the renovascular tolerance of AVD in the clinical setting. Methods: The MARS study is a multicentric prospective observational study of the renovascular safety of AVD in AVD-naive pts. 7 centres from 2009 to 2011. Data collected included: gender, age, serum creatinine (SCr), diabetes, HTN, hematuria (Hu) and Pu. This sub-group analysis presents the intermediate results for the 1st 155 pts with breast cancer (BC) receiving bevacizumab who completed the 1-year follow-up (f/u) (out of 337 BC pts in total). Results: Median age at inclusion: 62 years. Bone, visceral and cerebral metastasis frequencies were 74.2, 51.6 and 5.2%, respectively. Diabetes and HTN prevalences were 3.9% and 10.3%, respectively. Baseline renal assessment retrieved: Pu 14.2%, Hu 8.4%, aMDRD 98.2 ml/min/1.73m2 and 2 pts with aMDRD<60. The incidence of de novo Pu during f/u was 15% (Table). 59.1% of pts with Pu at inclusion improved. Among pts with de novo Pu, 40.0% afterwards improved/normalized. No grade 3/4 Pu has been reported and no hematuria. 12.9% developed HTN. Moreover, renal function decreased by -3.2 ml/min/1.73m2/year and 4 pts had aMDRD<60 at the end of f/u. 32.2% increased their SCr: 27.1% grade 1, 4.5% grade 2, and 0.6% grade 3. All pts with grade 2-3 returned to normal or grade 1. No thrombotic micro-angiopathy (TMA) has been reported. Conclusions: These results show that 1) TMA remains rare, 2) Pu developed in 15% of pts, with no grade 3/4, 3) less than 13% developed HTN and 4) renal function was only slightly impaired with transient elevations in SCr. Furthermore, in case of a renovascular effect, investigators followed the recommendations from the French Society of Nephrology (Halimi JM. Nephrol Ther 2008) and no treatment withdrawal for unmanageable renovascular toxicity occurred. [Table: see text]
Collapse
Affiliation(s)
| | - Nicolas Janus
- Service ICAR - Pitie-Salpetriere Hospital, Paris, France
| | | | | | | | | | - Jean-Philippe Spano
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | - Jean Christophe Thery
- Medical Oncology Department, AP-HP, Salpetriere Hospital, University Paris VI, Paris, France
| | | | - Francois Goldwasser
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | - Olivier Mir
- Cochin Teaching Hospital, AP-HP, Paris Descartes University, Sorbonne Paris Cité, Paris, France
| | | | - Stephane Oudard
- Medical Oncology, Georges Pompidou European Hospital, Paris, France
| | - Michel Azizi
- Arterial Hypertensive Department, Hôpital Européen Georges Pompidou, Paris, France
| | | | - Gilbert Deray
- Nephrology Department, Pitie-Salpetriere Hospital, Paris, France
| | | |
Collapse
|